Entero Therapeutics, Correlations
| ENTO Stock | 0.48 0.07 12.73% |
The current 90-days correlation between Entero Therapeutics, and CVR Energy is -0.21 (i.e., Very good diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Entero Therapeutics, Correlation With Market
Significant diversification
The correlation between Entero Therapeutics, and DJI is 0.05 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Entero Therapeutics, and DJI in the same portfolio, assuming nothing else is changed.
Entero |
Moving together with Entero Stock
Moving against Entero Stock
| 0.54 | ETON | Eton Pharmaceuticals | PairCorr |
| 0.51 | VIGL | Vigil Neuroscience | PairCorr |
| 0.45 | MGTX | MeiraGTx Holdings PLC Earnings Call This Week | PairCorr |
| 0.39 | NBY | NovaBay Pharmaceuticals | PairCorr |
| 0.35 | LLY | Eli Lilly | PairCorr |
| 0.61 | MDT | Medtronic PLC | PairCorr |
| 0.46 | BAX | Baxter International Sell-off Trend | PairCorr |
| 0.43 | SMMT | Summit Therapeutics PLC | PairCorr |
| 0.37 | ABBV | AbbVie Inc | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Entero Stock performing well and Entero Therapeutics, Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Entero Therapeutics,'s multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CVI | 2.16 | (0.07) | 0.00 | (0.49) | 0.00 | 4.26 | 12.26 | |||
| CTYMF | 3.31 | 0.74 | 0.15 | 3.12 | 3.15 | 9.00 | 27.62 | |||
| GTY | 0.95 | (0.02) | 0.00 | (0.14) | 0.00 | 2.21 | 4.93 | |||
| ACI | 1.22 | 0.19 | 0.12 | 0.19 | 1.55 | 3.42 | 9.41 | |||
| CPNG | 1.40 | (0.10) | 0.00 | (0.21) | 0.00 | 2.61 | 11.08 | |||
| CDE | 3.08 | (0.06) | 0.00 | (0.12) | 0.00 | 7.70 | 19.05 | |||
| EFRMF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SAND | 1.61 | 0.17 | 0.08 | 0.48 | 2.38 | 3.51 | 11.26 |
Entero Therapeutics, Corporate Management
| Jennifer SealeyVoyksner | Senior Development | Profile | |
| Sarah CPA | Chief Officer | Profile | |
| Amy ChandlerSkerkis | QA Affairs | Profile | |
| RPh MBA | Chief Officer | Profile | |
| Martin MBA | Senior Development | Profile |